Insmed price target raised to $83 from $74 at JPMorgan

JPMorgan raised the firm’s price target on Insmed (INSM) to $83 from $74 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q3 report. It now models a $50,000 list price at the brenso launch, higher than its prior assumption of $40,000.